Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 16;41(28):4472–4477. doi: 10.1200/JCO.23.00046

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 1. — Efficacy outcomes for evaluable patients per CNS RECIST v1.1 (n = 19). (A) Waterfall plot of maximum percent tumor change from baseline (only patients with target lesions are shown). (B) Kaplan-Meier graphical representation of intracranial PFS. (C) Swimmer plot showing individual duration of treatment, time to first dose modification, response, clinical outcome, and most commonly administered dose at data cutoff. (D) Kaplan-Meier graphical representation of OS for the full analysis set (N = 25). ^aTime to first dose modification due to any cause, including missed dose, AE, or others. For patients who had a dose modification (reduction or interruption) after initiation of treatment because of an AE, adagrasib could be restarted at the 600 mg twice a day dose following resolution of AEs if deemed appropriate. AE, adverse event; NE, not evaluable; OS, overall survival; PFS, progression-free survival.